緑内障治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 29
3.2 Classification 32
3.3 Symptoms 33
3.4 Diagnosis 34
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 41
4.3 Global Trends 42
4.3.1 US 43
4.3.2 5EU 44
4.3.3 Japan 45
4.4 Forecast Methodology 46
4.4.1 Sources Used 49
4.4.2 Forecast Assumptions and Methods 52
4.4.3 Sources Not Used 58
4.5 Epidemiological Forecast for Glaucoma (2013-2023) 59
4.5.1 Total Prevalent Cases of Glaucoma 59
4.5.2 Age-Specific Total Prevalent Cases of Glaucoma 60
4.5.3 Sex-Specific Total Prevalent Cases of Glaucoma 62
4.5.4 Age-Standardized Total Prevalence of Glaucoma 64
4.5.5 Total Prevalent Cases of Glaucoma, by Clinical Type 65
4.5.6 Total Prevalent Cases of NTG 67
4.5.7 Diagnosed Prevalent Cases of POAG and PACG 69
4.6 Discussion 72
4.6.1 Epidemiological Forecast Insight 72
4.6.2 Limitations of the Analysis 73
4.6.3 Strengths of the Analysis 74
5 Disease Management 75
5.1 Diagnosis and Treatment Overview 75
5.1.1 Diagnosis 75
5.1.2 Treatment Guidelines 76
5.1.3 Leading Prescribed Drugs 78
5.1.4 Clinical Practice 78
5.2 US 81
5.3 5EU 85
5.4 Japan 90
6 Competitive Assessment 94
6.1 Overview 94
6.2 Product Profiles – Main Brands and Drug Classes 96
6.2.1 Xalatan (latanoprost) 96
6.2.2 Lumigan (bimatoprost) 102
6.2.3 Travatan (travoprost) 106
6.2.4 Tapros (tafluprost) 110
6.2.5 Beta Blockers 117
6.2.6 Carbonic Anhydrase Inhibitors 122
6.2.7 Alpha-Adrenergic Agonists 126
6.2.8 Simbrinza (brinzolamide + brimonidine) 129
6.2.9 Glanatec (ripasudil hydrochloride hydrate) 132
7 Unmet Need and Opportunity 138
7.1 Overview 138
7.2 Simplified Dosing Regimen 142
7.2.1 Unmet Need 142
7.2.2 Gap Analysis 143
7.2.3 Opportunity 146
7.3 Reminder Systems 147
7.3.1 Unmet Need 147
7.3.2 Gap Analysis 147
7.3.3 Opportunity 148
7.4 Long-Acting Therapy 149
7.4.1 Unmet Need 149
7.4.2 Gap Analysis 150
7.4.3 Opportunity 151
7.5 New Classes of IOP-Lowering Drugs 153
7.5.1 Unmet Need 153
7.5.2 Gap Analysis 155
7.5.3 Opportunity 156
7.6 Neuroprotective Drugs 157
7.6.1 Unmet Need 157
7.6.2 Gap Analysis 159
7.6.3 Opportunity 161
7.7 Improved Diagnosis and Monitoring 162
7.7.1 Unmet Need 162
7.7.2 Gap Analysis 163
7.7.3 Opportunity 164
8 Pipeline Assessment 165
8.1 Overview 165
8.2 Clinical Trials 165
8.2.1 Clinical Trial Mapping 165
8.2.2 Clinical Trial Design 166
8.3 Promising Drugs in Clinical Development 167
8.3.1 Rhopressa 169
8.3.2 Roclatan 181
8.3.3 Vesneo 189
8.3.4 Bimatoprost SR 198
8.3.5 Trabodenoson 206
8.3.6 OPC-1085EL 214
8.3.7 DE-117 218
8.3.8 OXT-TP 221
8.4 Promising Drugs in Early-Stage Development 223
8.4.1 ROCK Inhibitor AMA-0076 223
8.4.2 Sustained-Release PGA Products 224
8.5 Other Drugs in Development 227
9 Current and Future Players 228
9.1 Overview 228
9.2 Trends in Corporate Strategy 230
9.3 Company Profiles 231
9.3.1 Pfizer 231
9.3.2 Alcon 232
9.3.3 Allergan 234
9.3.4 Santen 235
9.3.5 Aerie Pharmaceuticals 237
9.3.6 Inotek Pharmaceuticals 239
9.3.7 Bausch & Lomb 240
9.3.8 Kowa Company 241
9.3.9 Otsuka Pharmaceutical 242
10 Market Outlook 244
10.1 Global Markets 244
10.1.1 Forecast 244
10.1.2 Drivers and Barriers – Global Issues 250
10.2 US 250
10.2.1 Forecast 250
10.2.2 Key Events 255
10.2.3 Drivers and Barriers 255
10.3 5EU 256
10.3.1 Forecast 256
10.3.2 Key Events 262
10.3.3 Drivers and Barriers 263
10.4 Japan 263
10.4.1 Forecast 263
10.4.2 Key Events 267
10.4.3 Drivers and Barriers 268
11 Appendix 269
11.1 Bibliography 269
11.2 Abbreviations 310
11.3 Methodology 315
11.4 Forecasting Methodology 315
11.4.1 Percent Drug-Treated Patients 315
11.4.2 Drugs Included in Each Therapeutic Class 316
11.4.3 Launch and Patent Expiry Dates 317
11.4.4 General Pricing Assumptions 317
11.4.5 Individual Drug Assumptions 318
11.4.6 Pricing of Pipeline Agents 327
11.5 Primary Research – KOLs Interviewed for this Report 327
11.6 Primary Research – High-prescriber Survey 329
11.7 About the Authors 330
11.7.1 Analyst 330
11.7.2 Therapy Area Director 330
11.7.3 Epidemiologist 331
11.7.4 Global Head of Healthcare 331
11.8 About GlobalData 332
11.9 Disclaimer 332